NCT01108302

Brief Summary

This cluster randomized community-based trial is designed to test the hypothesis that the intramuscular administration of 10 IU of oxytocin in Uniject™ during the third stage of labor by an Auxiliary Nurse Midwife (ANM) at births occurring in homes, Sub-Centers and Primary Health Centers in Bagalkot, India will reduce the risk of postpartum hemorrhage by 44% (from 9% to 5%) relative to home births attended by the same type of provider who does not provide the intervention drug. The study will also document correct use of oxytocin in Uniject, adverse maternal and fetal events associated with inappropriate use and a number of indicators reflecting the programmatic feasibility of implementing this intervention.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Sep 2011

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 2, 2010

Completed
19 days until next milestone

First Posted

Study publicly available on registry

April 21, 2010

Completed
1.4 years until next milestone

Study Start

First participant enrolled

September 1, 2011

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
Last Updated

January 9, 2012

Status Verified

December 1, 2011

Enrollment Period

1.8 years

First QC Date

April 2, 2010

Last Update Submit

January 6, 2012

Conditions

Keywords

uterotonicoxytocinrandomized trialIndiacommunityhemorrhage

Outcome Measures

Primary Outcomes (1)

  • postpartum hemorrhage

    blood loss \>=500 ml after delivery of the baby, as measured through a plastic calibrated drape.

    after delivery of baby

Secondary Outcomes (4)

  • Oxytocin use before delivery

    labor and delivery

  • stillbirth

    pregnancy

  • neonatal death

    first month of life

  • need for neonatal resuscitation

    0-6 hours after birth

Study Arms (2)

PPH Treatment only

NO INTERVENTION

Auxilliary nurse midwives will be able to treat for PPH only, not provide Oxytocin in Uniject

Oxytocin in Uniject

EXPERIMENTAL

Auxilliary Nurse Midwives will provide 10IU Oxytocin in Uniject device IM immediately after delivery

Other: Oxytocin in Uniject

Interventions

10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby

Also known as: Pitocin, Syntocinon
Oxytocin in Uniject

Eligibility Criteria

Sexfemale
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • gestational age \>=28 wks at enrollment
  • anticipate spontaneous vaginal delivery
  • hemoglobin \>=8 gm/dl
  • delivery at home, sub-center, or primary health center
  • delivery attended by Auxilliary Nurse Midwife

You may not qualify if:

  • previous caesarean-section
  • scheduled for caesarean-section
  • antepartum bleeding during current pregnancy
  • blood pressure \>140mm of Hg systolic and \>90mm of Hg diastolic
  • in active labor at time of recruitment
  • high risk medical conditions (diabetes, cardiac ailments, seizures, placenta previa, anticipated breech delivery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Jawaharlal Nehru Medical College Women's and Children's Health Research Unit

Belagavi, Karnataka, India

Location

MeSH Terms

Conditions

Postpartum HemorrhageHemorrhage

Interventions

Oxytocin

Condition Hierarchy (Ancestors)

Obstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesPuerperal DisordersUterine HemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Pituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsPeptidesAmino Acids, Peptides, and Proteins

Study Officials

  • Cynthia Stanton, PhD

    Johns Hopkins Bloomberg School of Public Health

    PRINCIPAL INVESTIGATOR
  • Shivaprasad Goudar, MD

    JN Medical College, Belgaum, India

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

April 2, 2010

First Posted

April 21, 2010

Study Start

September 1, 2011

Primary Completion

June 1, 2013

Study Completion

June 1, 2013

Last Updated

January 9, 2012

Record last verified: 2011-12

Locations